When was Treadwell founded?

Treadwell was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Treadwell located?

Treadwell is headquartered in New York City, United States.

Who is the current CEO of Treadwell?

Michael W Tusche and Shane Burgess s of Treadwell.

How many employees does Treadwell have?

As of Jun 30, 2026, the latest employee count at Treadwell is 12.

Is Treadwell a funded company?

Treadwell is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Nov 18, 2021.

When was the latest funding round of Treadwell?

Treadwell's latest funding was a $***** Series B round on Nov 18, 2021, with participation from 6 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.39B in funding in 2026 to date.

Where does Treadwell rank among its competitors?

Treadwell ranks 1010th amongst 3290 active competitors, of which 1118 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Treadwell?

Treadwell's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Treadwell - 2026 Company Profile, Team, Funding & Competitors

Company Details

Treadwell develops therapeutics for cancer. The company's products pipeline includes CFI-400945 which is an orally active small molecule drug that selectively inhibits PLK4 (Polo-like Kinase 4). Inhibition of PLK4 exacerbates the genomic instability in cancer cells, leading to cell death.

Website: treadwelltx.com
Email ID: *****@treadwelltx.com

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Series B

Total Funding

$91M in 1 round

Latest Funding Round

Series B, Nov 18, 2021, $*****

Investors

Sino Biopharmaceutical & 5 more

Ranked

1010^th among 3290 active competitors

Employee Count

12 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2982 more

View Treadwell's full profile

Treadwell has raised a total funding of $91M over 1 round. Its latest funding round was a Series B round on Nov 18, 2021 for $*****. 6 investors participated in its latest round. Treadwell has 5 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Treadwell:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 18, 2021	9444212	Series B	2728521	2952050	9189098	1951074

Access funding benchmarks and valuations. Sign up today!

View details of Treadwell's funding rounds and investors

The founders of Treadwell is Tak Wah Mak. Shane Burgess and Michael W Tusche are the CEOs of Treadwell.

Here are the details of Treadwell's key team members:

Tak Wah Mak: Co-Founder of Treadwell.
Michael W Tusche: Co-CEO of Treadwell.
Contact Info: 1 email address
Shane Burgess: Co-CEO of Treadwell. They serve on the board of 1 company.
Contact Info: 1 email address

View details of Treadwell's Founder profiles and Board Members

Treadwell's employee count trend

Treadwell has 12 employees as of Jun 26. Here is Treadwell's employee count trend over the years:

Uncover Treadwell's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Treadwell include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Treadwell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1010th	Treadwell 2019, New York City (United States), Series B	Developer of therapeutics for cancer	$91M	Sino Biopharmaceutical, 3W Fund Management ... & 4 others	41/100